TrialThoracic cancer2022

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).

Juwhan Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.